Compare FHN & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHN | RZLT |
|---|---|---|
| Founded | 1864 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 187.3M |
| IPO Year | N/A | N/A |
| Metric | FHN | RZLT |
|---|---|---|
| Price | $24.53 | $2.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 6 |
| Target Price | ★ $24.61 | $12.33 |
| AVG Volume (30 Days) | 5.7M | ★ 14.0M |
| Earning Date | 01-15-2026 | 02-11-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 20.88 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $3,184,000,000.00 | N/A |
| Revenue This Year | $10.95 | N/A |
| Revenue Next Year | $2.82 | N/A |
| P/E Ratio | $14.83 | ★ N/A |
| Revenue Growth | ★ 3.68 | N/A |
| 52 Week Low | $15.19 | $1.07 |
| 52 Week High | $24.75 | $11.46 |
| Indicator | FHN | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 74.40 | 29.47 |
| Support Level | $23.54 | $1.78 |
| Resistance Level | $24.10 | $2.25 |
| Average True Range (ATR) | 0.44 | 0.58 |
| MACD | 0.11 | -0.48 |
| Stochastic Oscillator | 93.16 | 13.27 |
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.